This strategic cooperation is a deep integration of the innovative strength of locally produced medical devices and the resource advantages of the world's top medical technology enterprises, injecting new momentum into the development of the coronary intervention treatment field.

Kossel, as a local innovative enterprise deeply engaged in the vascular interventional field, always takes clinical needs as its guide and focuses on the research, development, and transformation of high-end medical devices. The independently developed Seledora...^®The Spinous Balloon, with its unique technical design, breaks through traditional treatment bottlenecks and provides precise solutions for the treatment of complex coronary artery diseases such as moderate to severe calcified lesions. As a global leader in medical technology, Medtronic has deep roots in China, possessing a mature marketing network covering the entire country, a professional clinical academic promotion system, and substantial industry resource accumulation, which can provide strong support for the market entry and widespread adoption of innovative products.

Both parties unanimously believe that this cooperation is not only a crucial step for Kossel's products to achieve scaled commercial application, but also an important measure for Medtronic to deepen its local cooperation strategy in China. By complementing each other's strengths, the aim is to accelerate the introduction of more clinically valuable solutions to the market and promote the improvement of treatment standards.

This strategic cooperation has far-reaching strategic significance for both parties. For Kossel, with the help of Medtronic's comprehensive system, it can quickly enhance Seledora.^®The accessibility of the spinous process balloon accelerates the commercialization and clinical transformation of locally-produced medical achievements in China. For Medtronic, engaging in innovative collaboration with Kossel, a local enterprise closer to clinical practice, allows for the integration of different strengths, fostering positive interaction between global experience and Chinese practice. This aims to respond more quickly to changes in the Chinese clinical landscape, better refine comprehensive solutions, and more effectively serve a complex and diverse patient population, driving coronary treatment towards a more standardized and sustainable direction!

China's healthcare is transitioning from "whether it exists" to "how good, how stable, and whether it is sustainable," becoming a highly valuable innovation landscape globally. Medtronic advocates that China's healthcare innovation should be rooted in the local context rather than replicating global experiences, adhering to long-termism, and making a local commitment around patients, clinical systems, and the innovation ecosystem. This collaboration with Kossel represents a win-win choice of complementary strengths, aiming to create an innovative pathway tailored to China's clinical needs, transforming commitments into long-term clinical value for the benefit of more patients.

The lack of mature solutions for complex coronary cases is the core driving force behind Kossel's continuous research and development. True innovation goes beyond technical feasibility; it requires standardized application, widespread promotion, and long-term validation, all of which rely on a mature system. "Collaborative creation" is an inevitable choice for Kossel's development, and Medtronic’s global capabilities and localized investment philosophy align closely with this vision. Centered on patients, both parties uphold systematic and long-term cooperation principles. This signing will advance local innovation to the next level, unlocking greater clinical value.

The expansion of patient scale and the increasing complexity of lesions are driving coronary intervention into a new phase characterized by multi-device combinations and precision treatment. Medtronic has consistently accompanied the growth of China’s coronary field, recognizing that single technologies can no longer meet clinical demands. The industry urgently requires complementary technical approaches and stable application systems, making local innovation increasingly vital. This collaboration with Kossel will integrate global experience with Chinese practice to refine solutions, serve complex patient populations, and promote standardized, sustainable development in coronary treatment.

Seledora^®The development of the spinous process balloon has undergone design verification, engineering optimization, and repeated iterations. The team has solidified its foundation in quality systems, production supply, and clinical technical support. This collaboration focuses on this product while placing greater emphasis on aligning collaborative mechanisms. In the future, Kossel will continue to deliver mature products, complementing Medtronic's strengths to optimize the product portfolio and technical capabilities. Through long-term synergy, both parties aim to amplify their respective advantages, providing the clinical field with richer and more reliable solutions.

Both parties will take this cooperation as an opportunity to establish a comprehensive and常态化 collaboration mechanism, and carry out in-depth cooperation in multiple dimensions such as product promotion, academic exchange, and clinical research. By integrating the dual advantages of R&D innovation and commercial operation, they will jointly build a more complete coronary intervention treatment ecosystem, continuously promote the advancement of cardiovascular disease diagnosis and treatment technology, and contribute to improving the health level of the people and assisting in the construction of "Healthy China."